Odanacatib

from Wikipedia, the free encyclopedia
Structural formula
Structure of odanacatib
General
Non-proprietary name Odanacatib
other names

(2 S ) - N - (1-Cyanocyclopropyl) -4-fluoro-4-methyl-2 - {[(1 S ) -2,2,2-trifluoro-1- [4- (4-methylsulfonylphenyl) phenyl] ethyl] amino} pentanamide ( IUPAC )

Molecular formula C 25 H 27 F 4 N 3 O 3 S
External identifiers / databases
CAS number 603139-19-1
EC number 682-460-8
ECHA InfoCard 100.207.747
PubChem 10152654
Wikidata Q2014070
Drug information
Drug class

Enzyme inhibitor

properties
Molar mass 525.56 g · mol -1
safety instructions
GHS hazard labeling
no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Odanacatib , development code MK-0822 , is an experimental compound for the treatment of osteoporosis and bone metastases .

Mechanism of action

Odanacatib selectively blocks the enzyme cathepsin K. This enzyme plays a key role in the breakdown of the bone matrix by osteoclasts .

The active ingredient was developed by MSD Sharp & Dohme .

Clinical testing

Odanacatib is not an approved medicine . The substance was in clinical phase III for the treatment of osteoporosis. Odanacatib was in clinical phase II for bone metastases caused by breast cancer . In 2016, MSD announced the discontinuation of further testing. Approval was not granted due to an increased risk of stroke.

further reading

Individual evidence

  1. This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
  2. JY Gauthier, N. Chauret, u. a .: The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. In: Bioorganic & medicinal chemistry letters Volume 18, number 3, February 2008, pp. 923-928, doi : 10.1016 / j.bmcl. 2007.12.047 . PMID 18226527 .
  3. clinicaltrials.gov: BMD Efficacy and Safety of Odanacatib in Postmenopausal Women. Retrieved March 27, 2011.
  4. clinicaltrials.gov: A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD). Retrieved March 27, 2011.
  5. Merck Provides Update on Odanacatib Development Program . In: Business Wire , September 2, 2016. 

Web links